Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty

• Status: Completed
• Trial end date: 2017-11-15
• Target enrollment: 0
• Participant gender: All

Summary

Patients undergoing Primary Total Knee Arthroplasty will be randomized to receive either multimodal single injection adductor canal block with sham infusion catheter or continuous infusion of local anesthetic (control) for postoperative analgesia.

Primary end point is pain scores at 30 hours post performance of block procedure.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Treatments: Bupivacaine; Clonidine; Epinephrine; Epinephryl borate; Racepinephrine

Criteria

Inclusion Criteria:

Patients will be eligible for inclusion in the study if they are:

• Age of 18 years old or older

• Scheduled to primary unilateral total knee arthroplasty.

• Patients must give written informed consent for anesthesia including continuous adductor canal block for postoperative analgesia prior to recruitment

Exclusion Criteria:

Patients will be excluded if they have:

• A contraindication to an adductor canal block or catheter placement including, but not limited to site infection, irritation, or refusal.

• Poorly controlled diabetes (A1C >8.0)

• Allergy to medications involves in this study (opioids, bupivacaine, buprenorphine, clonidine, or dexamethasone)

• Opioid use >40 mg of oxycodone daily, long-acting opioids.